<s id="wsj_1784.1"> 22
3 	 0 	 N/N 	 1 	 companies Two
3 	 1 	 N/N 	 1 	 companies major
3 	 2 	 N/N 	 1 	 companies drug
3 	 4 	 (S[dcl]\NP)/NP 	 1 	 companies posted
4 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 posted in
7 	 4 	 (S[dcl]\NP)/NP 	 2 	 earnings posted
7 	 5 	 N/N 	 1 	 earnings strong
7 	 6 	 N/N 	 1 	 earnings third-quarter
10 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 line in
10 	 11 	 (NP\NP)/NP 	 1 	 line with
12 	 11 	 (NP\NP)/NP 	 2 	 profits with
12 	 14 	 S[pss]\NP 	 1 	 profits reported <XB>
14 	 13 	 (S\NP)/(S\NP) 	 2 	 reported already
14 	 15 	 ((S\NP)\(S\NP))/NP 	 2 	 reported by
17 	 15 	 ((S\NP)\(S\NP))/NP 	 3 	 leaders by
17 	 16 	 N/N 	 1 	 leaders industry
19 	 20 	 (NP[nb]/N)\NP 	 2 	 analysts '
21 	 11 	 (NP\NP)/NP 	 2 	 expectations with
21 	 20 	 (NP[nb]/N)\NP 	 1 	 expectations '
<\s>
<s id="wsj_1784.2"> 12
2 	 1 	 N/N 	 1 	 Inc. Pfizer
2 	 4 	 S[pss]\NP 	 1 	 Inc. based <XB>
2 	 9 	 (S[dcl]\NP)/NP 	 1 	 Inc. reported
4 	 5 	 ((S\NP)\(S\NP))/NP 	 2 	 based in
7 	 5 	 ((S\NP)\(S\NP))/NP 	 3 	 York in
7 	 6 	 N/N 	 1 	 York New
9 	 0 	 S/S 	 1 	 reported But
11 	 9 	 (S[dcl]\NP)/NP 	 2 	 earnings reported
11 	 10 	 N/N 	 1 	 earnings flat
<\s>
<s id="wsj_1784.3"> 31
1 	 0 	 N/N 	 1 	 Corp. Schering-Plough
1 	 3 	 S[pss]\NP 	 1 	 Corp. based <XB>
1 	 9 	 (S[dcl]\NP)/NP 	 1 	 Corp. reported
3 	 4 	 ((S\NP)\(S\NP))/NP 	 2 	 based in
5 	 4 	 ((S\NP)\(S\NP))/NP 	 3 	 Madison in
7 	 4 	 ((S\NP)\(S\NP))/NP 	 3 	 N.J. in
9 	 16 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 reported as
12 	 11 	 (N/N)/(N/N) 	 2 	 % 21
13 	 9 	 (S[dcl]\NP)/NP 	 2 	 rise reported
13 	 10 	 NP[nb]/N 	 1 	 rise a
13 	 12 	 N/N 	 1 	 rise %
13 	 14 	 (NP\NP)/NP 	 1 	 rise in
15 	 14 	 (NP\NP)/NP 	 2 	 earnings in
20 	 17 	 N/N 	 1 	 Corp. American
20 	 18 	 N/N 	 1 	 Corp. Home
20 	 19 	 N/N 	 1 	 Corp. Products
20 	 21 	 (NP\NP)/NP 	 1 	 Corp. of
20 	 24 	 (S[dcl]\NP)/NP 	 1 	 Corp. posted
23 	 21 	 (NP\NP)/NP 	 2 	 York of
23 	 22 	 N/N 	 1 	 York New
24 	 16 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 posted as
27 	 26 	 (N/N)/(N/N) 	 2 	 % 11
28 	 24 	 (S[dcl]\NP)/NP 	 2 	 increase posted
28 	 25 	 NP[nb]/N 	 1 	 increase an
28 	 27 	 N/N 	 1 	 increase %
28 	 29 	 (NP\NP)/NP 	 1 	 increase in
30 	 29 	 (NP\NP)/NP 	 2 	 net in
<\s>
<s id="wsj_1784.4"> 2
2 	 0 	 N/N 	 1 	 Products American
2 	 1 	 N/N 	 1 	 Products Home
<\s>
<s id="wsj_1784.5"> 18
2 	 0 	 N/N 	 1 	 Products American
2 	 1 	 N/N 	 1 	 Products Home
2 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 Products said
4 	 7 	 (NP\NP)/NP 	 1 	 sales for
4 	 14 	 (S[dcl]\NP)/PP 	 1 	 sales were
6 	 7 	 (NP\NP)/NP 	 1 	 earnings for
6 	 14 	 (S[dcl]\NP)/PP 	 1 	 earnings were
10 	 7 	 (NP\NP)/NP 	 2 	 quarter for
10 	 8 	 NP[nb]/N 	 1 	 quarter the
10 	 9 	 N/N 	 1 	 quarter third
13 	 7 	 (NP\NP)/NP 	 2 	 months for
13 	 12 	 N/N 	 1 	 months nine
14 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 were said
15 	 14 	 (S[dcl]\NP)/PP 	 2 	 at were
17 	 15 	 PP/NP 	 1 	 levels at
17 	 16 	 N/N 	 1 	 levels record
<\s>
<s id="wsj_1784.6"> 16
0 	 1 	 (NP\NP)/NP 	 1 	 Sales for
0 	 5 	 S[dcl]\NP 	 1 	 Sales increased
4 	 1 	 (NP\NP)/NP 	 2 	 quarter for
4 	 2 	 NP[nb]/N 	 1 	 quarter the
4 	 3 	 N/N 	 1 	 quarter third
5 	 7 	 (S\NP)\(S\NP) 	 2 	 increased %
5 	 8 	 ((S\NP)\(S\NP))/NP 	 2 	 increased to
5 	 12 	 ((S\NP)\(S\NP))/NP 	 2 	 increased from
7 	 6 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 6.5
9 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
11 	 9 	 N/N[num] 	 1 	 billion $
11 	 10 	 N/N 	 1 	 billion 1.51
13 	 12 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
15 	 13 	 N/N[num] 	 1 	 billion $
15 	 14 	 N/N 	 1 	 billion 1.42
<\s>
<s id="wsj_1784.7"> 37
0 	 1 	 (NP\NP)/NP 	 1 	 Sales of
0 	 4 	 S[dcl]\NP 	 1 	 Sales increased
3 	 1 	 (NP\NP)/NP 	 2 	 products of
3 	 2 	 N/N 	 1 	 products health-care
4 	 6 	 (S\NP)\(S\NP) 	 2 	 increased %
4 	 7 	 ((S\NP)\(S\NP))/NP 	 2 	 increased in
4 	 12 	 ((S\NP)\(S\NP))/PP 	 2 	 increased based
6 	 5 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 6
10 	 7 	 ((S\NP)\(S\NP))/NP 	 3 	 quarter in
10 	 8 	 NP[nb]/N 	 1 	 quarter the
10 	 9 	 N/N 	 1 	 quarter third
12 	 15 	 (((S\NP)\(S\NP))\((S\NP)\(S\NP)))/NP 	 3 	 based on
13 	 12 	 ((S\NP)\(S\NP))/PP 	 3 	 in based
14 	 13 	 PP/NP 	 1 	 part in
17 	 15 	 (((S\NP)\(S\NP))\((S\NP)\(S\NP)))/NP 	 4 	 sales on
17 	 16 	 N/N 	 1 	 sales strong
17 	 18 	 (NP\NP)/NP 	 1 	 sales of
20 	 18 	 (NP\NP)/NP 	 2 	 drugs of
20 	 19 	 N/N 	 1 	 drugs prescription
20 	 22 	 (NP\NP)/NP 	 1 	 drugs as
22 	 21 	 (NP\NP)/(NP\NP) 	 2 	 as such
23 	 22 	 (NP\NP)/NP 	 2 	 Premarin as
27 	 22 	 (NP\NP)/NP 	 2 	 drug as
27 	 25 	 NP[nb]/N 	 1 	 drug an
27 	 26 	 N/N 	 1 	 drug estrogen-replacement
30 	 15 	 (((S\NP)\(S\NP))\((S\NP)\(S\NP)))/NP 	 4 	 sales on
30 	 31 	 (NP\NP)/NP 	 1 	 sales of
33 	 32 	 NP[nb]/N 	 1 	 company the
33 	 34 	 (NP[nb]/N)\NP 	 2 	 company 's
36 	 31 	 (NP\NP)/NP 	 2 	 formula of
36 	 34 	 (NP[nb]/N)\NP 	 1 	 formula 's
36 	 35 	 N/N 	 1 	 formula infant
<\s>
<s id="wsj_1784.8"> 28
2 	 0 	 N/N 	 1 	 Products American
2 	 1 	 N/N 	 1 	 Products Home
2 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 Products said
5 	 4 	 N/N 	 1 	 income net
5 	 6 	 (S[dcl]\NP)/PP 	 1 	 income benefited
6 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 benefited said
7 	 6 	 (S[dcl]\NP)/PP 	 2 	 from benefited
12 	 7 	 PP/NP 	 1 	 rate from
12 	 8 	 NP[nb]/N 	 1 	 rate a
12 	 9 	 N/N 	 1 	 rate lower
12 	 10 	 N/N 	 1 	 rate effective
12 	 11 	 N/N 	 1 	 rate tax
12 	 14 	 (S[ng]\NP)/NP 	 1 	 rate reflecting <XB>
16 	 14 	 (S[ng]\NP)/NP 	 2 	 reduction reflecting
16 	 15 	 NP[nb]/N 	 1 	 reduction a
16 	 17 	 (NP\NP)/NP 	 1 	 reduction of
20 	 17 	 (NP\NP)/NP 	 2 	 rates of
20 	 18 	 N/N 	 1 	 rates foreign
20 	 19 	 N/N 	 1 	 rates tax
24 	 7 	 PP/NP 	 1 	 operations from
24 	 23 	 N/N 	 1 	 operations additional
24 	 25 	 (NP\NP)/NP 	 1 	 operations in
27 	 25 	 (NP\NP)/NP 	 2 	 Rico in
27 	 26 	 N/N 	 1 	 Rico Puerto
<\s>
<s id="wsj_1784.9"> 22
0 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 Net was
0 	 3 	 S[pss]\NP 	 1 	 Net aided <XB>
2 	 1 	 (S\NP)/(S\NP) 	 2 	 was also
3 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 aided was
3 	 4 	 ((S\NP)\(S\NP))/NP 	 2 	 aided by
6 	 4 	 ((S\NP)\(S\NP))/NP 	 3 	 gain by
6 	 5 	 NP[nb]/N 	 1 	 gain a
6 	 7 	 (NP\NP)/NP 	 1 	 gain on
6 	 19 	 (S[adj]\NP)/NP 	 1 	 gain effective <XB>
9 	 7 	 (NP\NP)/NP 	 2 	 sale on
9 	 8 	 NP[nb]/N 	 1 	 sale the
9 	 10 	 (NP\NP)/NP 	 1 	 sale of
12 	 11 	 NP[nb]/N 	 1 	 company the
12 	 13 	 (NP[nb]/N)\NP 	 2 	 company 's
15 	 10 	 (NP\NP)/NP 	 2 	 interests of
15 	 13 	 (NP[nb]/N)\NP 	 1 	 interests 's
15 	 14 	 N/N 	 1 	 interests equity
15 	 16 	 (NP\NP)/NP 	 1 	 interests in
18 	 16 	 (NP\NP)/NP 	 2 	 Africa in
18 	 17 	 N/N 	 1 	 Africa South
20 	 19 	 (S[adj]\NP)/NP 	 2 	 Sept. effective
21 	 20 	 N/N[num] 	 1 	 1 Sept.
<\s>
<s id="wsj_1784.10"> 22
6 	 0 	 (S/S)/NP 	 2 	 trading In
6 	 1 	 N/N 	 1 	 trading New
6 	 2 	 N/N 	 1 	 trading York
6 	 3 	 N/N 	 1 	 trading Stock
6 	 4 	 N/N 	 1 	 trading Exchange
6 	 5 	 N/N 	 1 	 trading composite
11 	 9 	 N/N 	 1 	 Products American
11 	 10 	 N/N 	 1 	 Products Home
11 	 12 	 (S[dcl]\NP)/PP 	 1 	 Products closed
12 	 0 	 (S/S)/NP 	 1 	 closed In
12 	 7 	 S/S 	 1 	 closed yesterday
12 	 19 	 ((S\NP)\(S\NP))/NP 	 2 	 closed down
13 	 12 	 (S[dcl]\NP)/PP 	 2 	 at closed
14 	 13 	 PP/NP 	 1 	 $ at
14 	 16 	 (NP\NP)/N 	 1 	 $ a
15 	 14 	 N/N[num] 	 1 	 102.25 $
17 	 16 	 (NP\NP)/N 	 2 	 share a
21 	 19 	 ((S\NP)\(S\NP))/NP 	 3 	 cents down
21 	 20 	 N/N 	 1 	 cents 75
<\s>
<s id="wsj_1784.11"> 0
<\s>
<s id="wsj_1784.12"> 15
0 	 1 	 (S[dcl]\NP)/S[dcl] 	 1 	 Pfizer said
3 	 2 	 N/N 	 1 	 sales third-quarter
3 	 4 	 S[dcl]\NP 	 1 	 sales increased
4 	 1 	 (S[dcl]\NP)/S[dcl] 	 2 	 increased said
4 	 6 	 (S\NP)\(S\NP) 	 2 	 increased %
4 	 7 	 ((S\NP)\(S\NP))/NP 	 2 	 increased to
4 	 11 	 ((S\NP)\(S\NP))/NP 	 2 	 increased from
6 	 5 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 4
8 	 7 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
10 	 8 	 N/N[num] 	 1 	 billion $
10 	 9 	 N/N 	 1 	 billion 1.44
12 	 11 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
14 	 12 	 N/N[num] 	 1 	 billion $
14 	 13 	 N/N 	 1 	 billion 1.38
<\s>
<s id="wsj_1784.13"> 22
1 	 0 	 NP[nb]/N 	 1 	 company The
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 company said
4 	 3 	 N/N 	 1 	 income net
4 	 5 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 income was
4 	 6 	 S[adj]\NP 	 1 	 income flat <XB>
5 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 was said
5 	 7 	 ((S\NP)\(S\NP))/PP 	 2 	 was because
6 	 5 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 flat was
8 	 7 	 ((S\NP)\(S\NP))/PP 	 3 	 of because
9 	 8 	 PP/NP 	 1 	 investment of
9 	 10 	 (NP\NP)/NP 	 1 	 investment in
11 	 10 	 (NP\NP)/NP 	 2 	 research in
13 	 10 	 (NP\NP)/NP 	 2 	 development in
15 	 8 	 PP/NP 	 1 	 costs of
15 	 16 	 S[adj]\NP 	 1 	 costs related <XB>
16 	 17 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 2 	 related to
18 	 17 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 3 	 launches to
18 	 19 	 (NP\NP)/NP 	 1 	 launches of
21 	 19 	 (NP\NP)/NP 	 2 	 products of
21 	 20 	 N/N 	 1 	 products several
<\s>
<s id="wsj_1784.14"> 16
1 	 0 	 NP[nb]/N 	 1 	 company The
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 company said
4 	 3 	 NP[nb]/N 	 1 	 dollar the
4 	 5 	 (NP[nb]/N)\NP 	 2 	 dollar 's
7 	 5 	 (NP[nb]/N)\NP 	 1 	 strengthening 's
7 	 6 	 N/N 	 1 	 strengthening continued
7 	 8 	 (S[dcl]\NP)/NP 	 1 	 strengthening reduced
8 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 reduced said
8 	 12 	 ((S\NP)\(S\NP))/NP 	 2 	 reduced by
11 	 8 	 (S[dcl]\NP)/NP 	 2 	 growth reduced
11 	 9 	 N/N 	 1 	 growth world-wide
11 	 10 	 N/N 	 1 	 growth sales
15 	 12 	 ((S\NP)\(S\NP))/NP 	 3 	 points by
15 	 13 	 N/N 	 1 	 points three
15 	 14 	 N/N 	 1 	 points percentage
<\s>
<s id="wsj_1784.15"> 20
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 Pfizer posted
4 	 1 	 (S[dcl]\NP)/NP 	 2 	 gains posted
4 	 2 	 NP[nb]/N 	 1 	 gains its
4 	 3 	 N/N 	 1 	 gains largest
4 	 5 	 (NP\NP)/NP 	 1 	 gains in
7 	 5 	 (NP\NP)/NP 	 2 	 sales in
7 	 6 	 N/N 	 1 	 sales healthcare
7 	 9 	 (NP\NP)/NP 	 1 	 sales up
11 	 9 	 (NP\NP)/NP 	 2 	 % up
11 	 10 	 N/N 	 1 	 % 3
15 	 5 	 (NP\NP)/NP 	 2 	 products in
15 	 14 	 N/N 	 1 	 products consumer
15 	 17 	 (NP\NP)/NP 	 1 	 products up
19 	 17 	 (NP\NP)/NP 	 2 	 % up
19 	 18 	 N/N 	 1 	 % 23
<\s>
<s id="wsj_1784.16"> 21
0 	 1 	 (NP\NP)/NP 	 1 	 Sales by
0 	 9 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 Sales were
0 	 10 	 S[adj]\NP 	 1 	 Sales flat <XB>
4 	 1 	 (NP\NP)/NP 	 2 	 chemicals by
4 	 2 	 NP[nb]/N 	 1 	 chemicals the
4 	 3 	 N/N 	 1 	 chemicals specialty
8 	 1 	 (NP\NP)/NP 	 2 	 segments by
8 	 2 	 NP[nb]/N 	 1 	 segments the
8 	 3 	 N/N 	 1 	 segments specialty
8 	 6 	 N/N 	 1 	 segments materials
8 	 7 	 N/N 	 1 	 segments science
10 	 9 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 flat were
13 	 14 	 (NP\NP)/NP 	 1 	 sales by
13 	 18 	 S[dcl]\NP 	 1 	 sales declined
17 	 14 	 (NP\NP)/NP 	 2 	 segment by
17 	 15 	 NP[nb]/N 	 1 	 segment the
17 	 16 	 N/N 	 1 	 segment agriculture
18 	 20 	 (S\NP)\(S\NP) 	 2 	 declined %
20 	 19 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 5
<\s>
<s id="wsj_1784.17"> 18
3 	 0 	 (S/S)/NP 	 2 	 segment In
3 	 1 	 NP[nb]/N 	 1 	 segment the
3 	 2 	 N/N 	 1 	 segment health-care
6 	 5 	 N/N 	 1 	 sales pharmaceutical
6 	 7 	 S[dcl]\NP 	 1 	 sales increased
7 	 0 	 (S/S)/NP 	 1 	 increased In
7 	 9 	 (S\NP)\(S\NP) 	 2 	 increased %
9 	 8 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 4
11 	 12 	 (NP\NP)/NP 	 1 	 sales of
11 	 15 	 S[dcl]\NP 	 1 	 sales increased
14 	 12 	 (NP\NP)/NP 	 2 	 products of
14 	 13 	 N/N 	 1 	 products hospital
15 	 0 	 (S/S)/NP 	 1 	 increased In
15 	 17 	 (S\NP)\(S\NP) 	 2 	 increased %
17 	 16 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 1
<\s>
<s id="wsj_1784.18"> 33
2 	 0 	 (S/S)/NP 	 2 	 quarter During
2 	 1 	 NP[nb]/N 	 1 	 quarter the
4 	 5 	 (S[dcl]\NP)/NP 	 1 	 Pfizer received
5 	 0 	 (S/S)/NP 	 1 	 received During
7 	 5 	 (S[dcl]\NP)/NP 	 2 	 approval received
7 	 6 	 N/N 	 1 	 approval federal
7 	 8 	 (NP\NP)/NP 	 1 	 approval of
10 	 8 	 (NP\NP)/NP 	 2 	 XL of
10 	 9 	 N/N 	 1 	 XL Procardia
15 	 8 	 (NP\NP)/NP 	 2 	 blocker of
15 	 12 	 NP[nb]/N 	 1 	 blocker a
15 	 13 	 N/N 	 1 	 blocker calcium
15 	 14 	 N/N 	 1 	 blocker channel
15 	 16 	 (S[pss]\NP)/PP 	 1 	 blocker approved <XB>
17 	 16 	 (S[pss]\NP)/PP 	 2 	 for approved
19 	 17 	 PP/NP 	 1 	 angina for
19 	 18 	 NP[nb]/N 	 1 	 angina both
21 	 17 	 PP/NP 	 1 	 hypertension for
21 	 18 	 NP[nb]/N 	 1 	 hypertension both
25 	 8 	 (NP\NP)/NP 	 2 	 Piccolino of
25 	 24 	 N/N 	 1 	 Piccolino Monorail
25 	 27 	 (S[pss]\NP)/(S[to]\NP) 	 1 	 Piccolino used <XB>
25 	 29 	 (S[b]\NP)/NP 	 1 	 Piccolino open <XB>
28 	 27 	 (S[pss]\NP)/(S[to]\NP) 	 2 	 to used
29 	 28 	 (S[to]\NP)/(S[b]\NP) 	 2 	 open to
32 	 29 	 (S[b]\NP)/NP 	 2 	 arteries open
32 	 30 	 N/N 	 1 	 arteries obstructed
32 	 31 	 N/N 	 1 	 arteries coronary
<\s>
<s id="wsj_1784.19"> 20
6 	 0 	 (S/S)/NP 	 2 	 trading In
6 	 1 	 N/N 	 1 	 trading New
6 	 2 	 N/N 	 1 	 trading York
6 	 3 	 N/N 	 1 	 trading Stock
6 	 4 	 N/N 	 1 	 trading Exchange
6 	 5 	 N/N 	 1 	 trading composite
9 	 10 	 (S[dcl]\NP)/PP 	 1 	 Pfizer closed
10 	 0 	 (S/S)/NP 	 1 	 closed In
10 	 7 	 S/S 	 1 	 closed yesterday
10 	 17 	 ((S\NP)\(S\NP))/NP 	 2 	 closed up
11 	 10 	 (S[dcl]\NP)/PP 	 2 	 at closed
12 	 11 	 PP/NP 	 1 	 $ at
12 	 14 	 (NP\NP)/N 	 1 	 $ a
13 	 12 	 N/N[num] 	 1 	 67.75 $
15 	 14 	 (NP\NP)/N 	 2 	 share a
19 	 17 	 ((S\NP)\(S\NP))/NP 	 3 	 cents up
19 	 18 	 N/N 	 1 	 cents 75
<\s>
<s id="wsj_1784.20"> 0
<\s>
<s id="wsj_1784.21"> 14
0 	 1 	 (S[dcl]\NP)/S[dcl] 	 1 	 Schering-Plough said
2 	 3 	 (S[dcl]\NP)/NP 	 1 	 sales gained
3 	 1 	 (S[dcl]\NP)/S[dcl] 	 2 	 gained said
3 	 6 	 ((S\NP)\(S\NP))/NP 	 2 	 gained to
3 	 10 	 ((S\NP)\(S\NP))/NP 	 2 	 gained from
5 	 3 	 (S[dcl]\NP)/NP 	 2 	 % gained
5 	 4 	 N/N 	 1 	 % 2.7
7 	 6 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
9 	 7 	 N/N[num] 	 1 	 million $
9 	 8 	 N/N 	 1 	 million 743.7
11 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
13 	 11 	 N/N[num] 	 1 	 million $
13 	 12 	 N/N 	 1 	 million 724.4
<\s>
<s id="wsj_1784.22"> 42
2 	 0 	 (S/S)/NP 	 2 	 period In
2 	 1 	 NP[nb]/N 	 1 	 period the
5 	 4 	 NP[nb]/N 	 1 	 company the
5 	 6 	 (S[dcl]\NP)/NP 	 1 	 company completed
5 	 15 	 (S[dcl]\NP)/NP 	 1 	 company sold <XU>
5 	 25 	 (S[dcl]\NP)/NP 	 1 	 company announced <XU>
6 	 0 	 (S/S)/NP 	 1 	 completed In
8 	 6 	 (S[dcl]\NP)/NP 	 2 	 sale completed
8 	 7 	 NP[nb]/N 	 1 	 sale the
8 	 9 	 (NP\NP)/NP 	 1 	 sale of
13 	 9 	 (NP\NP)/NP 	 2 	 businesses of
13 	 10 	 NP[nb]/N 	 1 	 businesses its
13 	 11 	 N/N 	 1 	 businesses European
13 	 12 	 N/N 	 1 	 businesses cosmetics
15 	 0 	 (S/S)/NP 	 1 	 sold In
18 	 15 	 (S[dcl]\NP)/NP 	 2 	 interest sold
18 	 16 	 NP[nb]/N 	 1 	 interest a
18 	 17 	 N/N 	 1 	 interest majority
18 	 19 	 (NP\NP)/NP 	 1 	 interest in
22 	 19 	 (NP\NP)/NP 	 2 	 affiliate in
22 	 20 	 NP[nb]/N 	 1 	 affiliate its
22 	 21 	 N/N 	 1 	 affiliate Brazilian
25 	 0 	 (S/S)/NP 	 1 	 announced In
27 	 25 	 (S[dcl]\NP)/NP 	 2 	 reorganization announced
27 	 26 	 NP[nb]/N 	 1 	 reorganization the
27 	 28 	 (NP\NP)/NP 	 1 	 reorganization of
27 	 33 	 (NP\NP)/NP 	 1 	 reorganization into
32 	 28 	 (NP\NP)/NP 	 2 	 businesses of
32 	 29 	 NP[nb]/N 	 1 	 businesses its
32 	 30 	 N/N 	 1 	 businesses over-the-counter
32 	 31 	 N/N 	 1 	 businesses drug
36 	 33 	 (NP\NP)/NP 	 2 	 unit into
36 	 34 	 NP[nb]/N 	 1 	 unit a
36 	 35 	 N/N 	 1 	 unit new
41 	 33 	 (NP\NP)/NP 	 2 	 Products into
41 	 38 	 N/N 	 1 	 Products Schering-Plough
41 	 39 	 N/N 	 1 	 Products Health
41 	 40 	 N/N 	 1 	 Products Care
<\s>
<s id="wsj_1784.23"> 29
1 	 0 	 NP[nb]/N 	 1 	 actions These
1 	 2 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 actions did
1 	 4 	 (S[b]\NP)/NP 	 1 	 actions affect <XB>
2 	 3 	 (S\NP)\(S\NP) 	 2 	 did n't
4 	 2 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 affect did
4 	 6 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 affect because
5 	 4 	 (S[b]\NP)/NP 	 2 	 results affect
8 	 7 	 NP[nb]/N 	 1 	 gain the
8 	 9 	 (NP\NP)/NP 	 1 	 gain on
8 	 17 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 gain was
8 	 18 	 S[pss]\NP 	 1 	 gain offset <XB>
11 	 9 	 (NP\NP)/NP 	 2 	 sale on
11 	 10 	 NP[nb]/N 	 1 	 sale the
11 	 12 	 (NP\NP)/NP 	 1 	 sale of
16 	 12 	 (NP\NP)/NP 	 2 	 businesses of
16 	 13 	 NP[nb]/N 	 1 	 businesses the
16 	 14 	 N/N 	 1 	 businesses European
16 	 15 	 N/N 	 1 	 businesses cosmetics
17 	 6 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 was because
18 	 17 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 offset was
18 	 19 	 ((S\NP)\(S\NP))/NP 	 2 	 offset by
20 	 19 	 ((S\NP)\(S\NP))/NP 	 3 	 provisions by
20 	 21 	 (S[ng]\NP)/PP 	 1 	 provisions relating <XB>
22 	 21 	 (S[ng]\NP)/PP 	 2 	 to relating
25 	 22 	 PP/NP 	 1 	 divestiture to
25 	 23 	 NP[nb]/N 	 1 	 divestiture the
25 	 24 	 N/N 	 1 	 divestiture Brazil
28 	 22 	 PP/NP 	 1 	 restructuring to
28 	 23 	 NP[nb]/N 	 1 	 restructuring the
28 	 27 	 N/N 	 1 	 restructuring drug
<\s>
<s id="wsj_1784.24"> 27
2 	 0 	 N/N 	 1 	 sales U.S.
2 	 1 	 N/N 	 1 	 sales pharmaceutical
2 	 3 	 S[dcl]\NP 	 1 	 sales rose
2 	 7 	 S[pss]\NP 	 1 	 sales led <XB>
3 	 5 	 (S\NP)\(S\NP) 	 2 	 rose %
5 	 4 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 15
7 	 8 	 ((S\NP)\(S\NP))/NP 	 2 	 led by
14 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 products by
14 	 9 	 N/N 	 1 	 products allergy
14 	 11 	 N/N 	 1 	 products asthma
14 	 13 	 N/N 	 1 	 products cold
17 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 products by
17 	 16 	 N/N 	 1 	 products dermatological
19 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 anti-infectives by
22 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 products by
22 	 21 	 N/N 	 1 	 products anti-cancer
26 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 products by
26 	 25 	 N/N 	 1 	 products cardiovascular
<\s>
<s id="wsj_1784.25"> 15
3 	 0 	 N/N 	 1 	 sales World-wide
3 	 1 	 N/N 	 1 	 sales consumer
3 	 2 	 N/N 	 1 	 sales product
3 	 4 	 S[dcl]\NP 	 1 	 sales declined
4 	 6 	 (S\NP)\(S\NP) 	 2 	 declined %
4 	 9 	 ((S\NP)\(S\NP))/PP 	 2 	 declined because
6 	 5 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 12
9 	 8 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 because primarily
10 	 9 	 ((S\NP)\(S\NP))/PP 	 3 	 of because
14 	 10 	 PP/NP 	 1 	 sale of
14 	 11 	 NP[nb]/N 	 1 	 sale the
14 	 12 	 N/N 	 1 	 sale European
14 	 13 	 N/N 	 1 	 sale cosmetics
<\s>
<s id="wsj_1784.26"> 15
1 	 0 	 (N/N)/(N/N) 	 2 	 lower Significantly
2 	 1 	 N/N 	 1 	 sales lower
2 	 3 	 (NP\NP)/NP 	 1 	 sales of
2 	 9 	 (S[dcl]\NP)/NP 	 1 	 sales were
7 	 3 	 (NP\NP)/NP 	 2 	 aids of
7 	 4 	 N/N 	 1 	 aids Stay
7 	 5 	 N/N 	 1 	 aids Trim
7 	 6 	 N/N 	 1 	 aids diet
9 	 8 	 (S\NP)/(S\NP) 	 2 	 were also
11 	 9 	 (S[dcl]\NP)/NP 	 2 	 factor were
11 	 10 	 NP[nb]/N 	 1 	 factor a
11 	 12 	 (NP\NP)/NP 	 1 	 factor in
14 	 12 	 (NP\NP)/NP 	 2 	 drop in
14 	 13 	 NP[nb]/N 	 1 	 drop the
<\s>
<s id="wsj_1784.27"> 13
4 	 0 	 NP[nb]/N 	 1 	 line The
4 	 1 	 N/N 	 1 	 line Maybelline
4 	 2 	 N/N 	 1 	 line beauty
4 	 3 	 N/N 	 1 	 line product
4 	 5 	 (S[dcl]\NP)/NP 	 1 	 line had
5 	 8 	 ((S\NP)\(S\NP))/NP 	 2 	 had following
7 	 5 	 (S[dcl]\NP)/NP 	 2 	 sales had
7 	 6 	 N/N 	 1 	 sales higher
12 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 half following
12 	 9 	 NP[nb]/N 	 1 	 half a
12 	 10 	 N/N 	 1 	 half sluggish
12 	 11 	 N/N 	 1 	 half first
<\s>
<s id="wsj_1784.28"> 16
4 	 0 	 (S/S)/NP 	 2 	 trading In
4 	 1 	 N/N 	 1 	 trading Big
4 	 2 	 N/N 	 1 	 trading Board
4 	 3 	 N/N 	 1 	 trading composite
7 	 6 	 N/N 	 1 	 shares Schering-Plough
7 	 8 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 shares fell
7 	 12 	 (S[b]\NP)/PP 	 1 	 shares close <XB>
8 	 0 	 (S/S)/NP 	 1 	 fell In
8 	 10 	 (S\NP)\(S\NP) 	 2 	 fell cents
10 	 9 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 cents 75
11 	 8 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to fell
12 	 11 	 (S[to]\NP)/(S[b]\NP) 	 2 	 close to
13 	 12 	 (S[b]\NP)/PP 	 2 	 at close
14 	 13 	 PP/NP 	 1 	 $ at
15 	 14 	 N/N[num] 	 1 	 74.125 $
<\s>
